+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 8 Actively Recruiting clinical trials

R

Actively Recruiting

Researchers are evaluating the safety and effects of ritlecitinib, a medicine taken by mouth, for treating alopecia areata, a condition causing hair loss on the scalp, face, and other body areas. This study focuses on people 12 years and older who have lost 50% or more of their scalp hair and do not have other causes of hair loss. The study aims to compare two doses, 50 mg and 100 mg, of ritlecitinib and see if the higher dose is safe and effective. Participants in Part 1 are randomly assigned to receive either 50 mg or 100 mg of ritlecitinib once daily, with some re-randomization at 24 weeks based on their response. Part 2 includes adolescents aged 12 to less than 18 years who receive 100 mg once daily. The study compares these doses to each other and to data from previous studies without a placebo group within this trial. Participants take the study medicine by mouth daily for up to 48 weeks depending on their group. During the approximately 13-month study, participants visit the study site up to nine times for assessments including alopecia areata evaluations, physical exams, hearing tests, blood tests, chest X-rays, electrocardiograms, and scalp and eye photographs Part 1 only. They also complete questionnaires about their condition. Researchers measure hair loss severity using the Severity of Alopecia Tool SALT, monitor side effects, laboratory results, and overall safety throughout the trial.

Age: 12Years +All GendersPhase 3
148 locations
C

Actively Recruiting

Researchers are evaluating how well guselkumab works compared to risankizumab in people with moderately to severely active Crohns Disease, a long-term condition causing severe inflammation in the intestines. This Phase 3b study aims to compare the effectiveness and safety of these two treatments to better understand their impact on this condition. Participants will receive either guselkumab or risankizumab following specific dosing schedules. Those receiving guselkumab will get induction doses by subcutaneous injection at Weeks 0, 4, and 8, then maintenance doses every 4 weeks from Week 12 through Week 52. Participants in the risankizumab group will receive induction doses intravenously at Weeks 0, 4, and 8, followed by maintenance doses by subcutaneous injection every 8 weeks from Week 12 to Week 52. During the study, participants will be monitored for deep remission at Week 52, along with other outcomes like clinical remission, endoscopic response, and steroid-free remission. Safety will be assessed by tracking adverse events and lab test abnormalities up to Week 165. Follow-up will continue to evaluate long-term effects, with participant involvement lasting until study completion in 2030.

Age: 18Years +All GendersPhase 3
164 locations
R

Actively Recruiting

This trial is focused on adults aged 50 and older with mild to moderate Alzheimers disease. Researchers aim to evaluate the safety and tolerability of Zunveyl, a medication taken orally, during 12 weeks of routine use. The study also looks at how the drug affects neuropsychiatric symptoms and caregiver distress for these patients. Participants will take Zunveyl delayed-release tablets twice daily, starting with 5 mg from Weeks 1 to 4, then increasing to 10 mg twice daily from Weeks 5 to 12. This open-label, phase 4 study monitors participants throughout this 12-week treatment period to assess how well they tolerate the medication and to observe any side effects. During the study, participants and their caregivers will attend regular visits where assessments will be made including safety checks, neuropsychiatric evaluations using the Neuropsychiatric Inventory NPI-12, and measurements of caregiver distress. Researchers will track adverse events, treatment interruptions, dose reductions, and overall tolerability scores up to Week 17. The total participation lasts about 12 weeks with follow-up assessments to evaluate ongoing safety and effects.

Age: 50Years +All GendersPhase 4
22 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of an investigational eye drop called Apraclonidine Ophthalmic Solution 0.125% in adults experiencing redness caused by minor eye irritations. This Phase 3 study compares this solution to an inactive placebo Vehicle to assess its ability to reduce ocular redness. The trial is randomized and double-blinded, ensuring unbiased results. Participants will receive a single dose of the study treatment in each eye on the first day at the clinic. Then, they will self-administer one drop in each eye twice daily at home for about eight weeks, with the final dose given in the clinic on Day 56. Following a one-week break from treatment, participants return for a final visit on Day 63. Eye redness is measured at specific times before and after dosing to track changes. During the study, participants attend six clinic visits over approximately 10 weeks. Redness is assessed at multiple time points on Day 1 and during follow-up visits. Researchers monitor safety, including any adverse effects, and evaluate how the eye drops affect redness over time. The trial aims to provide detailed information on the treatments impact on ocular redness and participant safety throughout the study period.

Age: 18Years +All GendersPhase 3
5 locations
A

Actively Recruiting

Researchers are evaluating the effectiveness and safety of the Gixam device for detecting pre-cancer or cancer in the colon and rectum in adults aged 45 to 84 who are at average risk for colorectal cancer and have had a negative Fecal Immunochemical Test FIT result. The study aims to determine if the Gixam device can identify colorectal neoplasia missed by the FIT test by comparing its results to those from a standard screening colonoscopy. Participants will undergo three main procedures the Gixam test, a FIT sample collected at home and sent to a lab, and a standard screening colonoscopy. All enrolled participants will receive these interventions, with the colonoscopy serving as the reference standard to assess the accuracy of the Gixam device. The study focuses on screening and does not include treatment interventions. During the study, participants will complete the Gixam test and FIT, followed by the colonoscopy. Researchers will monitor safety from enrollment up to 30 days after, and efficacy outcomes will be assessed through study completion, averaging 30 days. The study involves evaluating test results, collecting safety data, and comparing findings to help determine if the Gixam device is a useful screening tool for colorectal cancer.

Age: 45Years - 84YearsAll GendersPhase Not Applicable
9 locations
S

Actively Recruiting

This trial evaluates the safety and effectiveness of ARTIA Reconstructive Tissue Matrix in adult women undergoing immediate, two-stage implant-based breast reconstruction following mastectomy. The study focuses on participants having either unilateral or bilateral mastectomy and aims to assess outcomes related to breast reconstruction complications and participant satisfaction. Participants will receive breast reconstruction using the ARTIA Tissue Matrix device in a two-stage prepectoral implant-based procedure. The study is open-label, non-randomized, and conducted across multiple centers. The follow-up includes monitoring for major complications after the first stage and adverse events for up to approximately 36 months. Throughout the study, participants will be monitored for complications related to breast reconstruction, reconstructive failure, capsular contracture, and changes in satisfaction with breasts using the BREAST-Q score. Safety assessments and adverse event tracking will continue up to three years. The total study duration extends until February 2031, with primary outcome assessments at 18 months and secondary measures up to 36 months.

Age: 18Years +FEMALEPhase 3
23 locations
R

Actively Recruiting

Researchers are conducting a Phase 3, randomized, open-label study comparing two ways of giving the drug frexalimabby subcutaneous under the skin injection every 4 weeks versus intravenous IV infusion every 4 weeksin adults aged 18 to 60 years with relapsing multiple sclerosis RMS or non-relapsing secondary progressive multiple sclerosis nrSPMS. The study aims to evaluate the pharmacokinetics, safety, and efficacy of these two administration methods in this population. Participants will receive frexalimab either through an IV infusion or by subcutaneous injection using an on-body delivery system OBDS, with the option for home self-administration starting after appropriate training in Part B of the study. The treatment period for Parts A and B combined lasts 48 weeks 12 months, with an optional Part C continuing until a long-term safety study begins. Scheduled visits occur monthly between weeks 4 and 24, then every 1 to 3 months in Part B, and every 6 months in Part C. Participants discontinuing treatment early will have additional follow-up visits. During the study, participants will undergo regular on-site visits for drug administration and monitoring. Researchers will collect blood samples to assess drug levels and immune responses, perform MRI scans to track brain lesions, and monitor safety through adverse event reporting and laboratory tests. The studys main outcomes include drug concentration measurements up to week 24 and safety and efficacy assessments up to week 96. Follow-up after treatment ends will continue for 6 months to observe any ongoing effects.

Age: 18Years - 60YearsAll GendersPhase 3
68 locations
S

Actively Recruiting

Researchers are investigating the safety and effectiveness of Phentolamine Ophthalmic Solution POS in adults who have previously undergone keratorefractive surgery and now experience decreased vision under low light, or mesopic, conditions. This Phase 3 trial compares POS to a placebo to determine if POS can improve night vision in this group. Participants will be randomly assigned to receive either 0.75% Phentolamine Ophthalmic Solution or a placebo eye drop once daily for two weeks. Weekly clinic visits during this period will include checkups and tests. Participants will also maintain a diary to record their daily medication use each evening. Throughout the study, participants will undergo various vision tests and questionnaires to measure changes in visual acuity under mesopic conditions and effects on night driving difficulties. Safety and vision improvements will be closely monitored during the two-week treatment and at follow-up visits. The trial is expected to last until August 2027.

Age: 18Years +All GendersPhase 3
20 locations